Non-Current Liabilities
Total Liabilities
Merck & Co. Total Liabilities decreased by 29.3% to $229M in Q1 2026 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2024
Last reportedQ1 2026May 4, 2026
How to read this metric
A rising trend relative to assets may indicate increasing financial leverage and potential solvency risk.
Detailed definition
Total liabilities represent the aggregate of all current and non-current financial obligations the company owes to exter...
Peer comparison
A universal metric used to compare the capital structure and debt burden across all companies.
Metric ID:
total_liabilitiesHistorical Data
3 periods
| Q4 '24 | Q4 '25 | Q1 '26 | |
|---|---|---|---|
| Value | $538M | $324M | $229M |
| QoQ Change | — | -39.8% | -29.3% |
| YoY Change | — | -39.8% | — |
Range$229M – $538M
Avg YoY Growth-39.8%
Median YoY Growth-39.8%
Current Streak2+ quarters decline
Product Breakdown
| Segment | Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 |
|---|---|---|---|---|
| Alliance revenue - Lenvima | $125M | $250M | $250M | $125M |
| Total | — | — | — | — |
Alliance revenue - Lenvima was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s total liabilities?
- Merck & Co. (MRK) reported total liabilities of $229M in Q1 2026.
- What does total liabilities mean?
- The sum of all money the company owes to others.